ANIX
Anixa Biosciences·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 4
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ANIX
Anixa Biosciences, Inc.
A biotechnology company focused on the treatment and prevention of cancer and infectious diseases
3150 Almaden Expressway, Suite 250, San Jose, CA 95118
--
Anixa Biosciences, Inc., a biotechnology company incorporated under the laws of the State of Delaware on November 5, 1982, is dedicated to the development of innovative therapies and vaccines that address key unmet needs in the field of oncology. The company's therapeutic program centers on the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor T-cell therapy that represents an advanced form of CAR-T technology, currently being developed by its subsidiary, Certainty Therapeutics, Inc., with an initial focus on ovarian cancer. In addition, Anixa's vaccine program includes the development of vaccines against breast and ovarian cancer, as well as an exploratory program aimed at applying similar mechanisms to develop other cancer vaccines against organ malignancies such as lung, colon and prostate cancers.
Company Financials
EPS
ANIX has released its 2025 Q4 earnings. EPS was reported at -0.09, versus the expected -0.09, meeting expectations. The chart below visualizes how ANIX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
